查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1922677

日本血友病市場報告：按類型、治療方法、療法和地區分類（2026-2034 年）

Japan Hemophilia Market Report by Type (Hemophilia A, Hemophilia B, Hemophilia C, and Others), Treatment (On-Demand, Prophylaxis), Therapy (Replacement Therapy, ITI Therapy, Gene Therapy), and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 119 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

2025年，日本血友病市場規模達9.78億美元。 IMARC Group預測，到2034年，該市場規模將達到16.598億美元，2026年至2034年的複合年成長率（CAGR）為6.94%。日本完善的醫療保健基礎設施、對早期診斷和有效治療的日益重視、不斷成長的研發活動、血友病治療的快速發展以及製藥公司和科技公司之間日益密切的企業合作，都是推動市場成長的關鍵因素。

血友病是一種罕見的遺傳性疾病，其特徵是血液無法正常凝固，導致出血不止。它是由血液中某些凝血蛋白（例如因子VIII和因子IX）缺乏或不足引起的。血友病主要分為兩種：A型血友病A和B型血友病，區別在於缺乏或減少的凝血因子類型。血友病的症狀多種多樣，包括頻繁流鼻血、容易瘀青、關節疼痛、輕微外傷後也會出現嚴重出血。診斷包括身體檢查、病歷評估以及各種實驗室檢查，包括基因檢測、阻礙要素檢測和凝血因子活性測定。血友病的治療方法多種多樣，包括替代療法、預防性治療、基因療法、促凝血藥物、疼痛管理策略和支持性護理。這些方法有助於預防出血發作、提高生活品質、減輕疼痛並最大限度地減少關節損傷。

日本血友病市場趨勢：

日本完善的醫療基礎設施為血友病患者的診斷和治療提供了便利，推動了市場成長。此外，日本高水準的醫療服務也促使人們更加重視早期診斷和有效管理，這同樣對市場成長產生了正面影響。公共和私人投資支持的研發活動活性化，也推動了市場成長。血友病治療領域的快速發展，例如長效凝血因子的研發和基因治療方法的探索，也為市場前景帶來了正面影響。此外，日本人口預期壽命的延長，使得對血友病等慢性疾病的長期管理需求增加，也推動了市場成長。政府為罕見疾病研究計劃提供的各種津貼和激勵措施也是推動市場成長的因素。同時，遠端醫療等技術的快速發展，使得患者，特別是居住在偏遠地區的患者，更容易獲得專家的診療，進一步促進了市場成長。此外，穿戴式健康監測技術的日益普及，尤其是針對特定血友病相關指標的客製化監測技術，也推動了市場成長。除此之外，日本廣泛​​採用國際治療指南和通訊協定，促進了醫療服務的標準化，提高了治療的可預測性和有效性，同時政府也加大了對某些先前無法獲得的治療方法和藥物的醫保覆蓋核准，這些都為市場成長提供了支持。

本報告解答的關鍵問題

  • 日本血友病市場目前發展狀況如何？您預計未來幾年它將如何發展？
  • 新冠疫情對日本血友病市場造成了哪些影響？
  • 日本血友病市場是如何根據治療方法類型進行細分的？
  • 日本血友病市場依治療方法分類的情況如何？
  • 日本血友病市場依治療方法分類的情況如何？
  • 請介紹一下日本血友病市場價值鏈的各個環節。
  • 日本血友病市場的主要促進因素和挑戰是什麼？
  • 日本血友病市場的結構是怎麼樣的？主要企業有哪些？
  • 日本血友病市場競爭有多激烈？

目錄

第1章：序言

第2章：調查範圍與調查方法

  • 調查目標
  • 相關利益者
  • 數據來源
  • 市場估值
  • 預測方法

第3章執行摘要

第4章：日本血友病市場－引言

  • 概述
  • 市場動態
  • 產業趨勢
  • 競爭資訊

第5章 日本血友病市場概覽

  • 過去和當前的市場趨勢（2020-2025）
  • 市場預測（2026-2034）

6. 日本血友病市場－按類型細分

  • A型血友病A
  • B型血友病
  • 血友病C
  • 其他

7. 日本血友病市場－依治療方法細分

  • 必要時接受治療
  • 預防性治療

第8章：日本血友病市場－依治療方式細分

  • 替代療法
  • 免疫耐受誘導療法（ITI療法）
  • 基因治療

第9章：日本血友病市場：依地區分類

  • 關東地區
  • 關西、近畿地區
  • 中部地區
  • 九州和沖繩地區
  • 東北部地區
  • 中國地區
  • 北海道地區
  • 四國地區

第10章：日本血友病市場：競爭格局

  • 概述
  • 市場結構
  • 市場公司定位
  • 關鍵成功策略
  • 競爭對手儀錶板
  • 企業估值象限

第11章主要企業概況

第12章：日本血友病市場：產業分析

  • 促進因素、限制因素和機遇
  • 波特五力分析
  • 價值鏈分析

第13章附錄

簡介目錄
Product Code: SR112026A18960

The Japan hemophilia market size reached USD 907.8 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,659.8 Million by 2034, exhibiting a growth rate (CAGR) of 6.94% during 2026-2034 . The robust healthcare infrastructure in Japan, increasing focus on early diagnosis and effective management, rising research and development (R&D) activities, rapid advancements in hemophilia care, and the growing corporate partnerships between pharmaceutical companies and tech firms represent some of the key factors driving the market.

Access the full market insights report Request Sample

Hemophilia refers to a rare genetic disorder characterized by the inability of the blood to clot properly, leading to prolonged bleeding. It is caused by the deficiency or absence of specific clotting proteins, such as Factor VIII or Factor IX, in the blood. It primarily occurs in two forms, such as Hemophilia A and Hemophilia B, distinguished by the specific clotting factor that is either reduced or missing. Hemophilia exhibits various symptoms such as frequent nosebleeds, easy bruising, joint pain, and severe bleeding from minor injuries. It is diagnosed through physical examination, medical history evaluation, genetic testing, inhibitor testing, and various laboratory tests, such as clotting factor assays. Hemophilia is treated using multiple methods, such as replacement therapy, prophylactic treatment, gene therapy, clot-promoting medications, pain management strategies, and supportive care. They aid in preventing bleeding episodes, improving quality of life, reducing pain, and minimizing joint damage.

JAPAN HEMOPHILIA MARKET TRENDS:

The robust healthcare infrastructure in Japan, facilitating easier access to diagnostics and treatment for hemophilia patients, is one of the major factors contributing to the market growth. Moreover, the increasing focus on early diagnosis and effective management of the condition due to the high standard of healthcare services in the country is positively impacting the market growth. Additionally, the rising research and development (R&D) activities, backed by public and private investments, are providing a thrust to the market growth. In line with this, rapid advancements in hemophilia care, such as the development of extended half-life clotting factors and exploration of gene therapy options, are creating a positive outlook for the market growth. Furthermore, the increasing life expectancy of the population in Japan, requiring the need for long-term management of chronic conditions like hemophilia, is providing a thrust to the market growth. In addition to this, the implementation of various government grants and incentives for research projects focused on rare diseases is acting as a growth-inducing factor. Along with this, rapid advancements such as telemedicine, which make it easier for patients to consult with specialists, especially for those living in remote areas, are boosting the market growth. Besides this, the increasing prevalence of wearable technologies for health monitoring that are customized to monitor specific variables related to hemophilia is catalyzing the market growth. Apart from this, the widespread adoption of international treatment guidelines and protocols in Japan that help standardize care and make treatment more predictable and effective is bolstering the market growth. In line with this, the growing government aid in insurance approvals for certain kinds of treatments and medications that were earlier difficult to access is fostering the market growth.

JAPAN HEMOPHILIA MARKET SEGMENTATION:

Type Insights:

  • To get detailed segment analysis of this market Request Sample
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others

Treatment Insights:

  • On-Demand
  • Prophylaxis
  • On-Demand
  • Prophylaxis

Therapy Insights:

  • Replacement Therapy
  • ITI Therapy
  • Gene Therapy
  • Replacement Therapy
  • ITI Therapy
  • Gene Therapy

Regional Insights:

  • To get detailed regional analysis of this market Request Sample
  • Kanto Region
  • Kansai/Kinki Region
  • Central/ Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • Kanto Region
  • Kansai/Kinki Region
  • Central/ Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

  • KEY QUESTIONS ANSWERED IN THIS REPORT
  • How has the Japan hemophilia market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan hemophilia market?
  • What is the breakup of the Japan hemophilia market on the basis of type?
  • What is the breakup of the Japan hemophilia market on the basis of treatment?
  • What is the breakup of the Japan hemophilia market on the basis of therapy?
  • What are the various stages in the value chain of the Japan hemophilia market?
  • What are the key driving factors and challenges in the Japan hemophilia?
  • What is the structure of the Japan hemophilia market and who are the key players?
  • What is the degree of competition in the Japan hemophilia market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Hemophilia Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Hemophilia Market Landscape

  • 5.1 Historical and Current Market Trends (2020-2025)
  • 5.2 Market Forecast (2026-2034)

6 Japan Hemophilia Market - Breakup by Type

  • 6.1 Hemophilia A
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2020-2025)
    • 6.1.3 Market Forecast (2026-2034)
  • 6.2 Hemophilia B
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2020-2025)
    • 6.2.3 Market Forecast (2026-2034)
  • 6.3 Hemophilia C
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2020-2025)
    • 6.3.3 Market Forecast (2026-2034)
  • 6.4 Others
    • 6.4.1 Historical and Current Market Trends (2020-2025)
    • 6.4.2 Market Forecast (2026-2034)

7 Japan Hemophilia Market - Breakup by Treatment

  • 7.1 On-Demand
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2020-2025)
    • 7.1.3 Market Forecast (2026-2034)
  • 7.2 Prophylaxis
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2020-2025)
    • 7.2.3 Market Forecast (2026-2034)

8 Japan Hemophilia Market - Breakup by Therapy

  • 8.1 Replacement Therapy
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2020-2025)
    • 8.1.3 Market Forecast (2026-2034)
  • 8.2 ITI Therapy
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2020-2025)
    • 8.2.3 Market Forecast (2026-2034)
  • 8.3 Gene Therapy
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2020-2025)
    • 8.3.3 Market Forecast (2026-2034)

9 Japan Hemophilia Market - Breakup by Region

  • 9.1 Kanto Region
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2020-2025)
    • 9.1.3 Market Breakup by Type
    • 9.1.4 Market Breakup by Treatment
    • 9.1.5 Market Breakup by Therapy
    • 9.1.6 Key Players
    • 9.1.7 Market Forecast (2026-2034)
  • 9.2 Kansai/Kinki Region
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2020-2025)
    • 9.2.3 Market Breakup by Type
    • 9.2.4 Market Breakup by Treatment
    • 9.2.5 Market Breakup by Therapy
    • 9.2.6 Key Players
    • 9.2.7 Market Forecast (2026-2034)
  • 9.3 Central/ Chubu Region
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2020-2025)
    • 9.3.3 Market Breakup by Type
    • 9.3.4 Market Breakup by Treatment
    • 9.3.5 Market Breakup by Therapy
    • 9.3.6 Key Players
    • 9.3.7 Market Forecast (2026-2034)
  • 9.4 Kyushu-Okinawa Region
    • 9.4.1 Overview
    • 9.4.2 Historical and Current Market Trends (2020-2025)
    • 9.4.3 Market Breakup by Type
    • 9.4.4 Market Breakup by Treatment
    • 9.4.5 Market Breakup by Therapy
    • 9.4.6 Key Players
    • 9.4.7 Market Forecast (2026-2034)
  • 9.5 Tohoku Region
    • 9.5.1 Overview
    • 9.5.2 Historical and Current Market Trends (2020-2025)
    • 9.5.3 Market Breakup by Type
    • 9.5.4 Market Breakup by Treatment
    • 9.5.5 Market Breakup by Therapy
    • 9.5.6 Key Players
    • 9.5.7 Market Forecast (2026-2034)
  • 9.6 Chugoku Region
    • 9.6.1 Overview
    • 9.6.2 Historical and Current Market Trends (2020-2025)
    • 9.6.3 Market Breakup by Type
    • 9.6.4 Market Breakup by Treatment
    • 9.6.5 Market Breakup by Therapy
    • 9.6.6 Key Players
    • 9.6.7 Market Forecast (2026-2034)
  • 9.7 Hokkaido Region
    • 9.7.1 Overview
    • 9.7.2 Historical and Current Market Trends (2020-2025)
    • 9.7.3 Market Breakup by Type
    • 9.7.4 Market Breakup by Treatment
    • 9.7.5 Market Breakup by Therapy
    • 9.7.6 Key Players
    • 9.7.7 Market Forecast (2026-2034)
  • 9.8 Shikoku Region
    • 9.8.1 Overview
    • 9.8.2 Historical and Current Market Trends (2020-2025)
    • 9.8.3 Market Breakup by Type
    • 9.8.4 Market Breakup by Treatment
    • 9.8.5 Market Breakup by Therapy
    • 9.8.6 Key Players
    • 9.8.7 Market Forecast (2026-2034)

10 Japan Hemophilia Market - Competitive Landscape

  • 10.1 Overview
  • 10.2 Market Structure
  • 10.3 Market Player Positioning
  • 10.4 Top Winning Strategies
  • 10.5 Competitive Dashboard
  • 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

  • 11.1 Company A
    • 11.1.1 Business Overview
    • 11.1.2 Service Offered
    • 11.1.3 Business Strategies
    • 11.1.4 SWOT Analysis
    • 11.1.5 Major News and Events
  • 11.2 Company B
    • 11.2.1 Business Overview
    • 11.2.2 Service Offered
    • 11.2.3 Business Strategies
    • 11.2.4 SWOT Analysis
    • 11.2.5 Major News and Events
  • 11.3 Company C
    • 11.3.1 Business Overview
    • 11.3.2 Service Offered
    • 11.3.3 Business Strategies
    • 11.3.4 SWOT Analysis
    • 11.3.5 Major News and Events
  • 11.4 Company D
    • 11.4.1 Business Overview
    • 11.4.2 Service Offered
    • 11.4.3 Business Strategies
    • 11.4.4 SWOT Analysis
    • 11.4.5 Major News and Events
  • 11.5 Company E
    • 11.5.1 Business Overview
    • 11.5.2 Service Offered
    • 11.5.3 Business Strategies
    • 11.5.4 SWOT Analysis
    • 11.5.5 Major News and Events

12 Japan Hemophilia Market - Industry Analysis

  • 12.1 Drivers, Restraints, and Opportunities
    • 12.1.1 Overview
    • 12.1.2 Drivers
    • 12.1.3 Restraints
    • 12.1.4 Opportunities
  • 12.2 Porters Five Forces Analysis
    • 12.2.1 Overview
    • 12.2.2 Bargaining Power of Buyers
    • 12.2.3 Bargaining Power of Suppliers
    • 12.2.4 Degree of Competition
    • 12.2.5 Threat of New Entrants
    • 12.2.6 Threat of Substitutes
  • 12.3 Value Chain Analysis

13 Appendix